Navigation Links
Oncothyreon announces commitments to purchase $11.1 million of company securities in a registered direct financing
Date:5/20/2009

SEATTLE, May 20 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX: ONY) announced today that it has obtained commitments from several investors to purchase approximately 3.88 million shares of its common stock and warrants to purchase approximately 2.91 million shares of its common stock for gross proceeds of approximately $11.1 million. The investors have agreed to purchase the shares and warrants for $2.85 per unit (each unit consisting of one share and a warrant to purchase 0.75 shares of common stock), which price represents approximately a 12% discount to the trailing 60-trading day volume weighted average price of $3.23. The exercise price of the warrants will be $3.92 per share. The warrants will be exercisable at any time on or after the six-month anniversary and prior to the fifth anniversary of the closing of the transaction. The closing of the offering is expected to take place on May 26, 2009, subject to satisfaction of customary closing conditions. Oncothyreon plans to use the proceeds from this financing for general corporate purposes. Boenning & Scattergood, Inc. acted as exclusive placement agent in the transaction.

A registration statement relating to these securities (File # 333-149837) has been declared effective by the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor, shall there be any sale of these securities in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. Any offer of these securities will be solely by means of a prospectus included in the registration statement and any prospectus supplement that may be issued with respect to such offering. Copies of the final prospectus, including the prospectus supplement when filed, can be obtained at the Securities and Exchange Commission's website, www.sec.gov, from Oncothyreon at its Seattle, Washington address below or Boenning & Scattergood, Inc. by calling 1-800-883-1212.

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer.


'/>"/>
SOURCE Oncothyreon Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Biomira announces plan to change name to Oncothyreon
2. Oncothyreon highlights corporate and clinical objectives for 2008
3. Oncothyreon to present at BIO CEO & Investor Conference
4. Oncothyreon launches new corporate website
5. Oncothyreons PX-478 is effective in preclinical model of human lung cancer
6. Oncothyreon announces March 10th webcast of fourth quarter and full year financial results conference call
7. Oncothyreon reports full year and fourth quarter 2007 financial results
8. Oncothyreon to present at upcoming investment conferences
9. Oncothyreon announces issuance of patent for PX-867
10. Oncothyreon announces effectiveness of shelf registration statement
11. Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... , June 28, 2017  Scientific Analytics, Inc.,s DARI ... showcased in front of thousands of healthcare providers at Premier ... 27.   Scientific Analytics, DARI Motion Health was debuted ... recognizes advances in healthcare while highlighting industry suppliers committed to ... ...
(Date:6/28/2017)... 28, 2017 Michael Zasloff , MD, ... School of Medicine, and Founder, Chairman and CEO of ... that has helped clarify the function of alpha-Synuclein (aS), ... neurodegenerative diseases. Denise Barbut , MD, FRCP, Co-Founder, ... senior co-author of the study. Published in ...
(Date:6/28/2017)... ... June 28, 2017 , ... ... with three research projects accepted for presentation at the 33rd Annual Meeting of ... participants – including some of the world’s top thought leaders in reproductive medicine ...
(Date:6/28/2017)... ... June 28, 2017 , ... ... for multiphysics computational fluid dynamics (CFD) simulation and analysis includes two new ... version 12.04 introduces Design Manager, allowing users to easily explore multiple design ...
Breaking Biology Technology:
(Date:3/23/2017)... -- The report "Gesture Recognition and Touchless Sensing Market by Technology ... Forecast to 2022", published by MarketsandMarkets, the market is expected to be worth ... and 2022. Continue Reading ... ... ...
(Date:3/22/2017)... , March 21, 2017 Optimove ... used by retailers such as 1-800-Flowers and AdoreMe, ... — Product Recommendations and Replenishment. Using Optimove,s machine learning ... personalized product and replenishment recommendations to their customers ... on predictions of customer intent drawn from a ...
(Date:3/20/2017)... PMD Healthcare announces the release of its ... System (WMS), a remote, real-time lung health monitoring and ... is a Medical Device, Digital Health, and Chronic Care ... innovative solutions that empower people to improve their healthcare ... developed the first ever personal spirometer, Spiro PD, which ...
Breaking Biology News(10 mins):